Quintrio
Home

Stock overview

Sanofi American Depositary Shares (Each representing one-half of one ordinary share)

SNY

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Last trade $47.67
Day change -$0.725 (-1.50%)
Day range $47.37 – $48.49
Volume 1,236,900
Market cap $116.19B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for SNY.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for SNY.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

The Motley Fool

Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

Regeneron Pharmaceuticals is highlighted as potentially the cheapest major biotech company, trading at approximately 21x trailing earnings with $16 billion in net cash. The company's stock has climbed over 40% in the past year, driven by strong performance from key products like Libtayo and Eylea HD, which posted record sales. With a robust pipeline of 50 candidates and a $1 billion upfront payment from an expanded Sanofi partnership, Regeneron appears well-positioned for future growth.

Zacks Investment Research

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

Moderna outlined its growth strategy at its 2026 Analyst Day, highlighting oncology as a key long-term opportunity with intismeran autogene for melanoma treatment. However, shares fell 7% as the company projected $4 billion in 2027 cash costs and $4-$4.5 billion annually through 2030, while providing limited visibility into 2027 and longer-term revenue growth.

GlobeNewswire Inc.

Windward Bio Announces Pricing of Initial Public Offering

Windward Bio Group AG, a clinical-stage biotechnology company developing ultra-long-acting antibody medicines, priced its IPO at $17.00 per share for 10.3 million shares, raising $225 million in gross proceeds. The company also completed a concurrent private placement with Sanofi for $50 million. Trading on Nasdaq under ticker WWB is expected to begin November 13, 2026, with offering closure on November 16, 2026.

Zacks Investment Research

REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?

Regeneron Pharmaceuticals (REGN) shares surged 27.4% over the past month, driven by strong third-quarter results. Eylea HD sales jumped 62% to $699 million, offsetting declining Eylea sales amid competition from Roche's Vabysmo. Strong Dupixent profits, oncology portfolio expansion, and a promising pipeline including cemdisiran for myasthenia gravis support long-term growth. The stock trades at an attractive valuation of 13.29X forward earnings, below historical and industry averages, earning a Zacks Rank #2 (Buy) rating.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
May 4, 2026$2.419Jun 3, 2026recurring
May 9, 2025$2.1953Jun 12, 2025recurring
May 9, 2024$2.0369Jun 6, 2024recurring
May 30, 2023$1.9001Jun 23, 2023recurring
May 4, 2022$1.7468May 31, 2022recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.